Loading...
Market
When will the first major milestone payment from Bristol Myers Squibb to Evotec occur under the new collaboration?
2
Resolution / Starting Odds
By Q1 2025 • 25%
By Q2 2025 • 25%
By Q3 2025 • 25%
By Q4 2025 • 25%
Official financial reports or press releases from Bristol Myers Squibb or Evotec
Story
Evotec and Bristol Myers Squibb Expand Proteomics Partnership with $50 Million Upfront
Oct 23, 2024, 06:02 AM
Evotec SE and Bristol Myers Squibb have announced an expansion of their proteomics partnership, which will now include a new molecular glue-based collaboration. This collaboration begins with a $50 million upfront payment from Bristol Myers Squibb to Evotec. The partnership aims to build a molecular glue-based pipeline, leveraging the success of previous deals between the two companies. The new collaboration focuses on non-protac degraders.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
Q3 2024 • 25%
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Yes • 50%
No • 50%